Cargando…

When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study

BACKGROUND: Opioid replacement treatment (ORT) with methadone is regarded as gold standard in the treatment of opioid addiction. Treatment doses of 60 mg methadone per day and above are associated with better treatment retention and reduction in the use of heroin and cocaine. However, an absolute do...

Descripción completa

Detalles Bibliográficos
Autores principales: Reimer, Jens, Boniakowski, Eduard, Bachner, Christian, Weber, Bernd, Tietje, Wieland, Verthein, Uwe, Walcher, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975916/
https://www.ncbi.nlm.nih.gov/pubmed/24581310
http://dx.doi.org/10.1186/1747-597X-9-13
_version_ 1782310209312522240
author Reimer, Jens
Boniakowski, Eduard
Bachner, Christian
Weber, Bernd
Tietje, Wieland
Verthein, Uwe
Walcher, Stephan
author_facet Reimer, Jens
Boniakowski, Eduard
Bachner, Christian
Weber, Bernd
Tietje, Wieland
Verthein, Uwe
Walcher, Stephan
author_sort Reimer, Jens
collection PubMed
description BACKGROUND: Opioid replacement treatment (ORT) with methadone is regarded as gold standard in the treatment of opioid addiction. Treatment doses of 60 mg methadone per day and above are associated with better treatment retention and reduction in the use of heroin and cocaine. However, an absolute dose level cannot function as parameter for adequate dosing. This study aims to determine dose adequacy in a sample of patients on stable methadone treatment, and to relate dose adequacy to disease severity. METHODS: This study was designed as open prospective cohort study over 12 months, with baseline data reported here. Patients on stable substitution treatment with methadone (Eptadone®) were consecutively included. Medical and socio-demographic data were gathered and the instruments Opiate Dosage Adequacy Scale (ODAS), European Addiction Severity Index (EuropASI) and the Derogatis Interview for Sexual Functioning – Self Report (DISF-SR) were applied. RESULTS: Five hundred and sixteen subjects, who received on average 60.3 (±30.4) mg methadone per day, were included. According to ODAS, 40.6% suffered from an inadequate dosing, and 59.4% had an adequate dose. Patients with an adequate dose received on average 57.8 (±27.5) mg methadone per day, whilst patients with an inadequate dose received on average 70.6 (±33.0) mg per day. The frequencies of patients with methadone doses of less than 60 mg per were 45.4% in the inadequate and 60.6% in the adequate group. The inadequate group suffered from a statistically significant higher burden of addiction related problems in all EuropASI domains. Sexual functioning did not differ by adequacy group, but women suffered from more pronounced sexual dysfunction as compared to men. CONCLUSION: A high frequency of inadequate dosing was found in this sample of patients on ORT. Higher disease severity should alert for possible need of even higher methadone doses. The tendency to low methadone doses warrants further research in the treatment system. Higher methadone doses are not related to increased sexual dysfunction. Sexual dysfunction, especially in women, should be considered in treatment.
format Online
Article
Text
id pubmed-3975916
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39759162014-04-05 When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study Reimer, Jens Boniakowski, Eduard Bachner, Christian Weber, Bernd Tietje, Wieland Verthein, Uwe Walcher, Stephan Subst Abuse Treat Prev Policy Research BACKGROUND: Opioid replacement treatment (ORT) with methadone is regarded as gold standard in the treatment of opioid addiction. Treatment doses of 60 mg methadone per day and above are associated with better treatment retention and reduction in the use of heroin and cocaine. However, an absolute dose level cannot function as parameter for adequate dosing. This study aims to determine dose adequacy in a sample of patients on stable methadone treatment, and to relate dose adequacy to disease severity. METHODS: This study was designed as open prospective cohort study over 12 months, with baseline data reported here. Patients on stable substitution treatment with methadone (Eptadone®) were consecutively included. Medical and socio-demographic data were gathered and the instruments Opiate Dosage Adequacy Scale (ODAS), European Addiction Severity Index (EuropASI) and the Derogatis Interview for Sexual Functioning – Self Report (DISF-SR) were applied. RESULTS: Five hundred and sixteen subjects, who received on average 60.3 (±30.4) mg methadone per day, were included. According to ODAS, 40.6% suffered from an inadequate dosing, and 59.4% had an adequate dose. Patients with an adequate dose received on average 57.8 (±27.5) mg methadone per day, whilst patients with an inadequate dose received on average 70.6 (±33.0) mg per day. The frequencies of patients with methadone doses of less than 60 mg per were 45.4% in the inadequate and 60.6% in the adequate group. The inadequate group suffered from a statistically significant higher burden of addiction related problems in all EuropASI domains. Sexual functioning did not differ by adequacy group, but women suffered from more pronounced sexual dysfunction as compared to men. CONCLUSION: A high frequency of inadequate dosing was found in this sample of patients on ORT. Higher disease severity should alert for possible need of even higher methadone doses. The tendency to low methadone doses warrants further research in the treatment system. Higher methadone doses are not related to increased sexual dysfunction. Sexual dysfunction, especially in women, should be considered in treatment. BioMed Central 2014-02-28 /pmc/articles/PMC3975916/ /pubmed/24581310 http://dx.doi.org/10.1186/1747-597X-9-13 Text en Copyright © 2014 Reimer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Reimer, Jens
Boniakowski, Eduard
Bachner, Christian
Weber, Bernd
Tietje, Wieland
Verthein, Uwe
Walcher, Stephan
When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
title When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
title_full When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
title_fullStr When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
title_full_unstemmed When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
title_short When higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
title_sort when higher doses in opioid replacement treatment are still inadequate – association to multidimensional illness severity: a cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3975916/
https://www.ncbi.nlm.nih.gov/pubmed/24581310
http://dx.doi.org/10.1186/1747-597X-9-13
work_keys_str_mv AT reimerjens whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy
AT boniakowskieduard whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy
AT bachnerchristian whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy
AT weberbernd whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy
AT tietjewieland whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy
AT vertheinuwe whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy
AT walcherstephan whenhigherdosesinopioidreplacementtreatmentarestillinadequateassociationtomultidimensionalillnessseverityacohortstudy